My watch list  

Vion Pharmaceuticals, Inc.

Vion Pharmaceuticals, Inc. (NASDAQ: VION) is a Connecticut based pharmaceutical company founded in March 1992 to commercialize several discoveries made in the biomedical laboratories at Yale University. Vion has been a publicly traded company on NASDAQ since 1995.

Clinical Development

Several anticancer programs are underway at Vion. Two small molecules, Cloretazine® (VNP40101M) and Triapine®, are in human clinical trials. Cloretazine® (VNP40101M), a novel alkylating agent, is in a Phase 3 trial in relapsed acute myelogenous leukemia (AML) and a Phase 2 trial in elderly de novo poor-risk AML. In addition, trials of Cloretazine® (VNP40101M) are underway in pediatric brain tumors, small cell lung cancer, and advanced hematologic malignancies. Triapine®, a ribonucleotide reductase inhibitor, is being evaluated in clinical trials sponsored by the National Cancer Institute.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Vion_Pharmaceuticals,_Inc.". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE